Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

GSK invests £10 million over five years to establish the Experimental Medicine Collaboration with the University of Oxford.

Researcher pipetting a solution into a tube © University of Oxford Images

The GSK and University of Oxford Experimental Medicine Collaboration (EMC) is a pioneering partnership that aims to redefine the approach to studying and treating immune mediated inflammatory diseases. Through the integration of cutting-edge molecular insights with clinical advancements, the EMC will allow testing of multiple medicines across cellular mechanisms in parallel.

The EMC will be led by Oxford’s Professor Christopher Buckley, Kennedy Trust Feldmann Maini Professor of Translational Medicine and Director of the Oxford Experimental Medicine Clinical Research Facility (EMCRF), alongside Dr Eric Olson, Vice President and Head of Early Development Leaders at GSK.

GSK will provide a £10 million infrastructure grant for the Oxford EMCRF, a National Institute of Health and Care Research (NIHR) supported clinical research facility providing a resource for early phase, experimental medicine studies across the Oxford Medical Sciences Division.

Dame Fiona Powrie, Director of the Kennedy Institute of Rheumatology and a Professor of Musculoskeletal Sciences at the University of Oxford, said: 'This exciting new collaboration represents the best of Oxford’s translational science in action. By partnering with GSK through the EMC, we aim to revolutionise how inflammatory diseases are studied and treated. This initiative brings together world-class expertise, cutting-edge facilities, and a bold approach to accelerate the transition from lab-based discovery to patient benefit.'

 

Read the full story on the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science website.

Similar stories

Breakthrough in non-invasive liver testing

Two major international studies, including an imaging study led by researchers from the Radcliffe Department of Medicine, have provided new evidence on which non-invasive tests can accurately diagnose and measure the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, MASH, potentially reducing reliance on liver biopsy.

Researchers from the Nuffield Department of Primary Care Health Sciences contribute to parliamentary calls for overhaul of obesity care

Research from the Health Behaviors team has informed a series of parliamentary reports calling for urgent action to tackle obesity in England.

Oxford University invites 100,000 people to take part in a major study of plant-based diets

Researchers at the Nuffield Department of Population Health have launched a major new study designed to generate the most up-to-date picture of different diets in the UK, including plant-based diets, and how they affect long-term health and wellbeing.

Look beyond my skin: your psoriasis could help us understand who develops psoriatic arthritis

Adults with psoriasis across Europe are invited to take part in an online study aiming to identify who is at risk of developing psoriatic arthritis.

Professor Matthew Wood receives BioUK Special Recognition Award 2026

Professor Matthew Wood, Director and Chief Scientific Officer of the Oxford-Harrington Rare Disease Centre (OHC), has received BioUK’s Special Recognition Award 2026 for his contribution to rare disease research, therapeutic development and the wider life sciences sector.

University of Oxford and BIIE launch collaboration in translational immune engineering

Researchers from the Department of Paediatrics at the University of Oxford and the Botnar Institute of Immune Engineering (BIIE) came together in Oxford last week for the inaugural scientific meeting of the new Basel–Oxford Centre for Translational Immune Engineering for Child and Adolescent Health (CTIE).